Developing and Embracing a Culture of Quality in the Pharmaceutical Industry
Track
:
Track 12: Pharmaceutical Quality
Program Code:
216
Date:
Tuesday, June 25, 2013
Time:
8:00 AM to 9:30 AM
EST
Location:
153C
CHAIR
:
Mary Oates, PhD (SCHNON), Vice President, Global Quality Operations and EHS, Pfizer Inc, United States
Mary Oates is the Vice President of Global Quality Operations and EHS for Pfizer Global Supply. She is active in a variety of industry initiatives and holds a PhD in Analytical Chemistry.
SPEAKER
(S):
Christine M. V. Moore, PhD (SPKAGY), Acting Director, Office of New Drug Quality Assessment, OPS, CDER, FDA, United States
Dr. Moore is currently the Acting Director of CDER's Office of New Drug Quality Assessment (ONDQA) where she is at the forefront of development and implementation of agency QbD initiatives. She is a PhD Chemical Engineer with extensive experience in API process development and manufacturing.
Guy Villax, (SPKNON), Chief Executive Officer, Hovione, Portugal
Guy Villax has been the CEO of Hovione since 1997. Prior to that, he held positions with Price Waterhouse in London and Hovione in the Far East. He is a member of the board of CEFIC’s European Fine Chemicals Group and the RX-360 International Pharmaceutical Supply Chain Consortium.
David A. Tainsh, PhD,RPh (SPKNON), Chief Product Quality Officer, Governance, Ethics and Assurance, GlaxoSmithKline, United Kingdom
PhD Pharmacist with 30yrs industrial experience, 25 at GSK. Appointed to a new corporate role - Chief Product Quality Officer in 2011, with oversight responsibility for the governance and control framework of Product Quality across GSK. Former Global Head of Pharmaceutical Development from 2006
Description
Reliable availability of quality medicines requires more than following the rules laid down by regulators. Today's complex, global environment demands that all participants in the supply chain adopt a culture of quality, a culture in which every employee understands and embraces their responsibility for delivering quality outcomes that benefit patients. This focus on quality outcomes must exist across the product life cycle, including product and process development, clinical trials, regulatory submissions and commercial manufacturing. The session will define the characteristics of a quality culture across a range of firms and functions, describe how to assess existing culture and achieve the desired state and outline the benefits for patients, regulators and the pharmaceutical industry.